Biogen Idec’s executive vice president of Research & Development, Douglas Williams said it best: “What’s hot in biotech? I’d say damn near everything.”
Williams, of course, was kicking off the festivities at Xconomy Boston’s latest life sciences event, “What’s Hot in Boston Biotech,” on April 16. Attendees then got a taste of the big ideas floating around the local biotech scene, from gene editing to “super-enhancers” to microbiome drug cocktails. Last week I posted a recap of the event, and today I’m circling back with some of the photos.
Once again, a tip of the cap to KeithSpiroPhoto, courtesy of Kendall Press, for all the pictures. And a big thank you to our speakers, our event host, Biogen, and our sponsors: Cubist Pharmaceuticals; Health Advances; Icon; Mintz Levin; and Rasky Baerlein. And a special thanks to our National Partner, Alexandria Real Estate Equities.
Author: Ben Fidler
Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
View all posts by Ben Fidler
